Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
- Abstract
- Background/Aims
Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naïve patients with CHB living in Daejeon and Chungcheong Province, South Korea.
Methods
One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months.
Results
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were 184 ± 188 IU/L, 150 ± 138 IU/L, and 7.1 ± 1.2 log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough.
Conclusions
Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough.
- All Author(s)
- H. W. Yang
; B. S. Lee
; T. H. Lee
; H. Y. Lee
; K. W. Nam
; Y. W. Kang
; H. B. Chae
; S. H. Kim
; S. B. Kim
; H. I. Lee
; A. N. Kim
; I. H. Song
; S. H. Lee
; H. S. Kim
- Issued Date
- 2010
- Type
- Article
- Keyword
- Clevudine; Drug resistance; HBV seroconversion; Hepatitis B, chronic
- Publisher
- 대한내과학회
Korean Association of Internal Medicine
- ISSN
- 1226-3303
; 2005-6648
- Citation Title
- The Korean journal of internal medicine
- Citation Volume
- 25
- Citation Number
- 4
- Citation Start Page
- 372
- Citation End Page
- 376
- Language(ISO)
- eng
- DOI
- 10.3904/kjim.2010.25.4.372
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/3237
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.